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which required the exclusion of ambivalent cases. As detailed
in our paper, some were unclassiﬁable because of exposure to
additional renal stressors (e.g., nephrotoxins) after enrollment,
which altered the relationships between initial urine sampling
and subsequent serum creatinine dynamics and outcomes.
Accordingly, neither serum creatinine nor uNGAL were
predictive of clinical outcomes in this sub-population. Whether
uNGAL discriminated intrinsic AKI correctly in these
unclassiﬁable patients simply could not be assessed based on
our strict, a priori deﬁnitions of prerenal and intrinsic AKI.
In sum, we consider uNGAL a promising candidate
marker to address the unquestionable limitations of using
serum creatinine as a sole marker of intrinsic kidney damage.
Larger studies with a multicentric design will soon be avail-
able to further address the potential of NGAL in situations
that demand prospective data.
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Warfarin-related nephropathy
To the Editor: In the July (2) 2011 issue, Brodsky et al.1
purport to demonstrate the consequences of warfarin-related
nephropathy (WRN) among a retrospective cohort from
the Ohio State University Medical Center. The cohort
selection procedure was designed to yield cases of ‘pre-
sumptive’ WRN, but may have resulted in selection bias:
patients who had a creatinine measured within 1 week of an
international normalized ratio (INR) 43 were selected. It is
possible that the selection regimen produced a cohort
enriched in subjects with acute illnesses, and it was the latter,
rather than ‘WRN’, that was responsible for the rise in serum
creatinine. In support of this alternative hypothesis is the fact
that ‘WRN’ cases had more frequent preexisting heart failure
and chronic kidney disease, which would leave them prone
to acute deterioration. The mortality hazard associated with
‘WRN’ was concentrated within the ﬁrst few weeks after the
initial INR elevation, which is consistent with the alter-
native hypothesis. The latter would also explain why drugs
expected to both increase and decrease glomerular capillary
pressure were associated with ‘WRN’, as both would tend
to be used in patients who are acutely ill. Further, the analysis
was restricted to only the ﬁrst INR elevation. One would
expect the latter to select for patients new to anticoagulation
therapy or those who had started other medications that
interfered with anticoagulant metabolism. In both cases, the
sampling would select for patients with acute illness. Thus,
the observed association between the creatinine elevation
(presumptive WRN) and mortality risk may have been
confounded.
1. Brodsky SV, Nadasdy T, Rovin BH et al. Warfarin-related nephropathy
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is associated with an increased mortality rate. Kid Int 2011; 80:
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Table 1 |Multiple logistic regression models for the
prediction of a composite renal outcome (step-up in RIFLE
severity class or dialysis initiation)
Parameter P-value Odds ratioa R2-value AUC–ROCa
Biomarker model
Age (470 years) 0.171 0.6 (0.2–1.3) 0.189 0.74 (0.63–0.85)
Serum creatinine
(4205mmol/l)
0.048 2.4 (1.0–5.6)
Urinary NGAL
(4104mg/l)
0.002 4.3 (1.7–10.5)
Conventional model
Age (470 years) 0.151 0.6 (0.2–1.2) 0.081 0.66 (0.55–0.76)
Serum creatinine
(4205mmol/l)
0.021 2.7 (1.2–6.1)
Abbreviations: AUC, area under the curve; NGAL, neutrophil gelatinase-associated
lipocalin; RIFLE, risk, injury, failure, loss, end-stage renal disease; ROC, receiver
operating characteristic.
aData in parentheses are 95% confidence intervals.
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